"Biomarker-Defined Subsets of Common Diseases: Policy and Economic Implications of Orphan Drug Act Coverage"

LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Aaron Kesselheim and colleagues examine orphan-designated drugs approved between 2009 and 2015 in the United States. Click to show full abstract

Aaron Kesselheim and colleagues examine orphan-designated drugs approved between 2009 and 2015 in the United States.

Keywords: diseases policy; biomarker defined; common diseases; defined subsets; policy economic; subsets common

Journal Title: PLoS Medicine
Year Published: 2017

Link to full text (if available)

Share on Social Media: Sign Up to like & get
recommendations!
0

LAUSR

You are not signed in:

Sign Up!

Related content

More Information News Social Media Video Recommended